Medytox announced on the 7th that its botulinum toxin preparation ‘Medytoxin’ (export name Neuronox) had recently obtained marketing approval in Malaysia and Saudi Arabia, and its hyaluronic acid filler ‘Neuramis’ in Brazil and the Philippines, respectively.
The company explains that Malaysia and Saudi Arabia, where Medytoxin has entered the market, are attracting attention as important bases for targeting the Islamic market as the middle class has recently increased and the demand for aesthetics is growing.
Neuramis has recently obtained product approvals in Brazil and the Philippines, and has entered 44 countries around the world. In addition, it is planning to obtain approval for marketing in Taiwan, Mexico, and El Salvador within this year, and plans to actively utilize the European CE certification possessed by the three Neuramis series to become a true global filler brand.
An official from Medytox said, “As the global phase 3 clinical trial of the new botulinum toxin formulation exported to Allergan is in the final stage, we will be able to apply for a product license (BLA) to the US FDA early next year.”
